Codagenix Inc. Announces Award of $1M US Army Contract for Continued Development of Contemporary Balanced Dengue Vaccine

Codagenix Inc. Announces Award of $1M US Army Contract for Continued Development of Contemporary, Balanced Dengue Vaccine

13:51 EDT 27 Apr 2019 | Synbiobeta

Farmingdale, New York, April 24, 2019 – Codagenix, Inc., announces today the awarding of a U.S. Department of Defense (DOD) Phase II SBIR contract to continue the development and testing of a live attenuated, quadrivalent vaccine against Dengue virus (DENV) – based on contemporary strains of Dengue virus. A Military Prioritization Panel hosted by the […]

More From BioPortfolio on "Codagenix Inc. Announces Award of $1M US Army Contract for Continued Development of Contemporary, Balanced Dengue Vaccine"